Switch theme
Sign up to access all valuation multiples
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
2019
73
LTM Revenue $7.8M
LTM EBITDA -$91.5M
$524M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Taysha GTx has a last 12-month revenue (LTM) of $7.8M and a last 12-month EBITDA of -$91.5M.
In the most recent fiscal year, Taysha GTx achieved revenue of $8.3M and an EBITDA of -$88.0M.
Taysha GTx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Taysha GTx valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.8M | XXX | $8.3M | XXX | XXX | XXX |
| Gross Profit | $7.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 99% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$91.5M | XXX | -$88.0M | XXX | XXX | XXX |
| EBITDA Margin | -1166% | XXX | -1055% | XXX | XXX | XXX |
| EBIT | -$92.8M | XXX | -$86.6M | XXX | XXX | XXX |
| EBIT Margin | -1183% | XXX | -1039% | XXX | XXX | XXX |
| Net Profit | -$91.5M | XXX | -$89.3M | XXX | XXX | XXX |
| Net Margin | -1167% | XXX | -1072% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Taysha GTx's stock price is $3.
Taysha GTx has current market cap of $580M, and EV of $524M.
See Taysha GTx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $524M | $580M | XXX | XXX | XXX | XXX | $-0.35 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Taysha GTx has market cap of $580M and EV of $524M.
Taysha GTx's trades at 62.9x EV/Revenue multiple, and -6.0x EV/EBITDA.
Equity research analysts estimate Taysha GTx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Taysha GTx has a P/E ratio of -6.3x.
See valuation multiples for Taysha GTx and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $580M | XXX | $580M | XXX | XXX | XXX |
| EV (current) | $524M | XXX | $524M | XXX | XXX | XXX |
| EV/Revenue | 66.9x | XXX | 62.9x | XXX | XXX | XXX |
| EV/EBITDA | -5.7x | XXX | -6.0x | XXX | XXX | XXX |
| EV/EBIT | -5.7x | XXX | -6.1x | XXX | XXX | XXX |
| EV/Gross Profit | 67.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.3x | XXX | -6.5x | XXX | XXX | XXX |
| EV/FCF | -6.6x | XXX | -6.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTaysha GTx's last 12 month revenue growth is -18%
Taysha GTx's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.3M for the same period.
Taysha GTx's rule of 40 is -699% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Taysha GTx's rule of X is -1211% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Taysha GTx and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -18% | XXX | -19% | XXX | XXX | XXX |
| EBITDA Margin | -1166% | XXX | -1055% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -699% | XXX | -1073% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -1211% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 792% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1139% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Taysha GTx acquired XXX companies to date.
Last acquisition by Taysha GTx was XXXXXXXX, XXXXX XXXXX XXXXXX . Taysha GTx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Taysha GTx founded? | Taysha GTx was founded in 2019. |
| Where is Taysha GTx headquartered? | Taysha GTx is headquartered in United States of America. |
| How many employees does Taysha GTx have? | As of today, Taysha GTx has 73 employees. |
| Who is the CEO of Taysha GTx? | Taysha GTx's CEO is Mr. Sean P. Nolan. |
| Is Taysha GTx publicy listed? | Yes, Taysha GTx is a public company listed on NAS. |
| What is the stock symbol of Taysha GTx? | Taysha GTx trades under TSHA ticker. |
| When did Taysha GTx go public? | Taysha GTx went public in 2020. |
| Who are competitors of Taysha GTx? | Similar companies to Taysha GTx include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Taysha GTx? | Taysha GTx's current market cap is $580M |
| What is the current revenue of Taysha GTx? | Taysha GTx's last 12 months revenue is $7.8M. |
| What is the current revenue growth of Taysha GTx? | Taysha GTx revenue growth (NTM/LTM) is -18%. |
| What is the current EV/Revenue multiple of Taysha GTx? | Current revenue multiple of Taysha GTx is 66.9x. |
| Is Taysha GTx profitable? | Yes, Taysha GTx is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Taysha GTx? | Taysha GTx's last 12 months EBITDA is -$91.5M. |
| What is Taysha GTx's EBITDA margin? | Taysha GTx's last 12 months EBITDA margin is -1166%. |
| What is the current EV/EBITDA multiple of Taysha GTx? | Current EBITDA multiple of Taysha GTx is -5.7x. |
| What is the current FCF of Taysha GTx? | Taysha GTx's last 12 months FCF is -$80.0M. |
| What is Taysha GTx's FCF margin? | Taysha GTx's last 12 months FCF margin is -1020%. |
| What is the current EV/FCF multiple of Taysha GTx? | Current FCF multiple of Taysha GTx is -6.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
